Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial
RCT (n=150) found number of days without need for cardiovascular organ support was not different between patients receiving this humanised, monoclonal, non-neutralising, adrenomedullin antibody or placebo (12.37 vs 14.05 days; p=0.37) at 30 days and also no improved survival.
Source:
The Lancet Respiratory Medicine
SPS commentary:
Adrenomedullin is released during cardiogenic shock and is involved in its pathophysiological processes. According to a commentary, many inflammatory cytokines, including inducible nitric oxide synthase, TNF α, and interleukins have been implicated in facilitating systemic inflammatory response syndrome physiology in cardiogenic shock, primarily through altering catecholamine responsiveness, increasing vasodilation, and negative inotropy. It notes that despite these observations, efforts to identify inflammation and its surrogate markers as potential therapeutic targets in managing cardiogenic shock have been unsuccessful.